Jazz Pharmaceuticals has received U.S. FDA approval for Ziihera® (zanidatamab-hrii) to treat adults with HER2-positive (IHC 3+) biliary tract cancer (BTC).

Avirmax Biopharma Reports Dosing of First Patient in ABI-110 Clinical Study, a Novel Gene Therapy for Wet AMD with PCV.

Celldex reports that the first participant has received a dose in a Phase 1 study involving healthy volunteers for CDX-622.

LAPIX Therapeutics Reveals Favorable Phase 1 Clinical Trial Results for LPX-TI641 in Treating Autoimmune Disorders.

uniQure N.V. has announced that the initial patient has received the dose in the GenTLE Phase I/IIa clinical study of AMT-260.

Laekna has partnered with Lilly to advance LAE102, a new monoclonal antibody aimed at Activin Receptor Type 2A for obesity treatment.

The EC has given the green light to Pfizer’s HYMPAVZI™ (marstacimab) for treating severe Hemophilia A or B in adults and teens without inhibitors.

Eli Lilly and Company has announced encouraging Phase 2 findings for muvalaplin, which is a genetically linked risk factor for heart disease.

Nektar Therapeutics Shares Initial Preclinical Findings for its New CSF-1 Program, NKTR-422, at the 2024 ACR Convergence.

Icotrokinra provided impressive skin improvement and proven safety as a once daily tablet in Phase 3 results.

Neurizon Therapeutics Limited is excited to report favorable outcomes from a preclinical evaluation of its primary candidate, NUZ-001.

Virion Therapeutics announces initial clinical responses from VRON-0200, a new checkpoint modifier aimed at achieving functional cure for HBV, during The Liver Meeting® at AASLD.